TLL2

Across TCGA pan-cancer cohorts, TLL2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TLL2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher TLL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TLL2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CESC show a favorable association.

SCLC, UCEC, and PRAD are the cancer types where TLL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.055	0.708	<.001	36	view →
UCEC	DFS	Median	III,IV	1.000	0.523	.007	34	view →
PRAD	OS	Median	All	0.080	0.990	<.001	12	view →
SKCM	OS	Median	IV	0.415	0.861	.014	6	view →
LUAD	OS	Median	All	0.468	0.683	.033	4	view →
CESC	DFS	Median	All	1.000	0.520	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TLL2–SCLC (OS)

Open the SCLC breakdown →